BiologicsMD

470 James Street, Suite 007 (District-New Haven)
New Haven, CT 06513

Phone: (267) 394-1665
Website: https://www.biologicsmd.com/

Email: david.owens@biologicsmd.com

General Information:

BiologicsMD is a private drug discovery and development company that focuses on novel and highly targeted agonists and antagonists to the PTH/PTHrP receptor for advanced treatments in hair loss conditions, bone disorders and prevention of bone metastases. We are funded through Connecticut Innovations and private investors and are seeking our first institutional raise to complete our first in-human clinical trials that we believe could lead to an early exit.  We have formed a close relationship with thought-leading physicians in alopecia from Yale University and other centers of excellence. Our lead program, BMD-1141 has been shown to reverse hair loss quickly in animal models of chemotherapy-induced alopecia and alopecia areata.  Currently no reliable animal model of androgenetic alopecia (male pattern baldness) is available, but the mechanism by which BMD-1141 works clearly matches the mechanism that could reverse this common form of alopecia. Alhough a small company today, BiologicsMD is committed to building its presence in the State of Connecticut and contributing to the already robust biopharmaceutical ecosystem.

Research Activities:

BiologicsMD’s lead asset, BMD-1141, is a patent-protected, first-in-class hair cycle stimulator for the treatment of various types of non-scarring alopecia including alopecia areata, chemotherapy-induced alopecia, and androgenetic alopecia. BMD-1141 has a novel mechanism of action and is expected to promote hair growth more effectively, with subcutaneous dosing every 1-6 months, without the serious side effects of existing treatments.The pre-clinical data package for the treatment of alopecia includes multiple animal models, providing clear evidence of efficacy and safety. Importantly, the safety profile generated from in vitro and in vivo studies of BMD-1141 demonstrate no siginfiant risk factors. Related to the mechanism of action, BMD-1141, even at 10x the maximally efficacious dose, does not result in hypercalcemia. The manufacturing platform data includes formulations and long-term stability. BiologicsMD is currently in the process of raising their first institutional round of $17MM to fund a phase IA clinical trial in a population enriched with androgenetic alopecia subjects, and a phase IB clinical trial in alopecia areata patients. Upcoming research activities include clinical batch manufacturing and IND-enabling toxicology. Completion of these steps and the phase IA clinical trial is expected to take 27 months.